Synlogic Stock News

Synlogic (NASDAQ:SYBX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The companys []

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.

Shares of Synlogic, Inc. (NASDAQ:SYBX) have earned an average recommendation of Buy from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued a report on the stock in the last []

Zacks Investment Research upgraded shares of Synlogic (NASDAQ:SYBX) from a hold rating to a buy rating in a report published on Wednesday, Zacks.com reports. The brokerage currently has $2.75 price objective on the biotechnology companys stock. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based []

Zacks Investment Research upgraded shares of Synlogic (NASDAQ:SYBX) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, Zacks.com reports. They currently have $2.75 target price on the biotechnology companys stock. According to Zacks, Synlogic, Inc. engaged in the development of a novel class of living Synthetic []

Oppenheimer upgraded shares of Synlogic (NASDAQ:SYBX) from a market perform rating to an outperform rating in a research report report published on Wednesday morning, Price Targets.com reports. The firm currently has $7.00 target price on the biotechnology companys stock. SYBX has been the subject of several other reports. HC Wainwright dropped their price objective on []

Equities analysts expect Synlogic, Inc. (NASDAQ:SYBX) to announce ($0.28) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Synlogics earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.33). Synlogic posted earnings of ($0.39) per share during the []

Synlogic Inc (NASDAQ:SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, stock fell 1.52% (As on Nov 26, 10:46:42 AM UTC-4, The post Synlogic Inc (NASDAQ:SYBX) Upgraded by Oppenheimer to Outperform appeared first on FXDailyReport.Com .

Synlogic (NASDAQ:SYBX) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings Network reports. The firm currently has a $7.00 target price on the biotechnology company’s stock. Oppenheimer’s price target points to a potential upside of […]

Synlogic (NASDAQ:SYBX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm currently has a $2.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 4.17% from the stock’s current price. According […]

Squarepoint Ops LLC reduced its holdings in Synlogic, Inc. (NASDAQ:SYBX) by 67.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,599 shares of the biotechnology companys stock after selling 85,714 shares during the quarter. Squarepoint Ops LLC owned approximately 0.08% of Synlogic []

Wall Street analysts forecast that Synlogic, Inc. (NASDAQ:SYBX) will report $330,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Synlogics earnings. The highest sales estimate is $400,000.00 and the lowest is $250,000.00. The firm is scheduled to report its next earnings results on Thursday, March []

CAMBRIDGE, Mass., Nov. 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of interim data from the company''s Phase 2 SynPheny-1 clinical trial showing that

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2021 Results - Earnings Call Transcript